{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:34:26Z","timestamp":1782902066918,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the National Key Technologies R&D Program for the 13th Five-year Plan","award":["2017ZX10202101-001"],"award-info":[{"award-number":["2017ZX10202101-001"]}]},{"name":"the National Key Technologies R&D Program for the 12th Five-year Plan","award":["2012ZX10001003-001"],"award-info":[{"award-number":["2012ZX10001003-001"]}]},{"name":"the CAMS Initiative for Innovative Medicine","award":["CAMS-12M: 2017-12M-1-014"],"award-info":[{"award-number":["CAMS-12M: 2017-12M-1-014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The plasma concentration of patients treated with efavirenz (EFV) 600\u2009mg was found to exceed the upper limit of the proposed therapeutic window in most Chinese HIV-infected individuals; thus, dosage reduction of EFV to 400\u2009mg daily warranted consideration. This study aimed to assess the pharmacodynamics of EFV 400\u2009mg for HIV-1-infected patients in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Twenty cART-na\u00efve individuals were enrolled in this study. EFV 400\u2009mg combined with tenofovir (TDF) and lamivudine (3TC) as an initial antiretroviral regimen was administered for 48\u2009weeks. EFV concentration and T cell subsets as well as HIV RNA load were evaluated at baseline and at 4, 12, 24, and 48\u2009weeks. Moreover, neuropsychiatric adverse effects were also assessed by the Hamilton depression (HAMD) scale and Pittsburgh sleep quality index (PSQI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighteen males and two females whose median age was 26 (interquartile range [IQR]: 23\u201332) years completed 48\u2009weeks of follow-up. The median EFV concentrations were 1.88 (IQR: 1.54\u20132.42), 1.74 (IQR: 1.36\u20131.93), 1.93 (IQR: 1.66\u20132.22), and 1.85 (IQR: 1.54\u20132.14) mg\/L at weeks 4, 12, 24, and 48, respectively. The viral load was 4.59 (IQR: 4.10\u20135.19) log\n                      <jats:sub>10<\/jats:sub>\n                      copies\/mL at baseline, and it decreased by 4.6 (IQR: 3.98\u20135.18) log\n                      <jats:sub>10<\/jats:sub>\n                      copies\/mL from baseline to week 48. Three of 20 (15%), 10 of 20 (50.0%), 17 of 20 (85%), and 18 of 19 (95%) participants had a plasma viral load less than 50 copies\/mL at weeks 4, 12, 24, and 48, respectively. The median CD4 cell count was 330 (IQR: 237\u2013410) cells\/\u03bcL at baseline, and it increased to 473 (IQR: 344\u2013574) cells\/\u03bcL at 48\u2009weeks. The HAMD score was 5 (IQR: 3\u20139.8) and 3 (IQR: 2.25\u20134) at baseline and 48\u2009weeks, respectively. The PSQI score was 4 (IQR: 2\u20135.8) and 3 (IQR: 2\u20134) at baseline and 48\u2009weeks, respectively. Dizziness was the most common event, occurring in 70% of patients within the first 2 weeks of treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients prescribed with EFV 400\u2009mg-containing agents demonstrated favourable virological and immunological responses. And the plasma EFV concentration was within the recommended therapeutic range, with fewer adverse reactions than with EFV 600\u2009mg. EFV 400\u2009mg was effective and safe in Chinese HIV-infected patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04596488?term=NCT04596488&amp;draw=2&amp;rank=1\">NCT04596488<\/jats:ext-link>\n                      ; Registered 21 October, 2020; Retrospectively registered.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-05802-8","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T06:03:02Z","timestamp":1611381782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacodynamics of efavirenz 400 mg in treatment-na\u00efve Chinese HIV-infected patients in a prospective cohort study"],"prefix":"10.1186","volume":"21","author":[{"given":"Ling","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7050-5675","authenticated-orcid":false,"given":"Taisheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,23]]},"reference":[{"key":"5802_CR1","unstructured":"UNAIDS. https:\/\/www.unaids.org\/en\/site-search"},{"key":"5802_CR2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. USA: Department of Health and Human Services; 2019. Available at https:\/\/www.files. aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf. Accessed 19 Jun 2020."},{"key":"5802_CR3","unstructured":"EACS Guidelines version 9.1, October 2018. 2018. http:\/\/www.eacsociety. org\/files\/2018_guidelines-9.1-english.pdf. ."},{"issue":"4","key":"5802_CR4","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/QAD.0000000000002126","volume":"33","author":"Long-Term Virological Suppression Working Group for the Collaboration of Observational HIV Epidemiological Research Europe","year":"2019","unstructured":"Long-Term Virological Suppression Working Group for the Collaboration of Observational HIV Epidemiological Research Europe. (COHERE) in EuroCoord. Long-term virological suppression on first-line efavirenz\u200a+\u200atenofovir\u200a+\u200aemtricitabine\/lamivudine for HIV-1. AIDS. 2019;33(4):745\u201351.","journal-title":"AIDS."},{"key":"5802_CR5","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization. June, 2013."},{"issue":"1","key":"5802_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","volume":"63","author":"JK Rockstroh","year":"2013","unstructured":"Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1- infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63(1):77\u201385.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"19","key":"5802_CR7","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"SL Walmsley","year":"2013","unstructured":"Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Guti\u00e9rrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807\u201318.","journal-title":"N Engl J Med"},{"issue":"11","key":"5802_CR8","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1097\/QAD.0b013e328353b047","volume":"26","author":"A Scourfield","year":"2012","unstructured":"Scourfield A, Zheng J, Chinthapalli S, Waters L, Martin T, Mandalia S, et al. Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals. AIDS. 2012;26(11):1399\u2013401.","journal-title":"AIDS."},{"issue":"11","key":"5802_CR9","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1086\/497835","volume":"41","author":"F Guti\u00e9rrez","year":"2005","unstructured":"Guti\u00e9rrez F, Navarro A, Chinthapalli S, Waters L, Martin T, Mandalia S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005;41(11):1648\u201353.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"5802_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","volume":"15","author":"C Marzolini","year":"2001","unstructured":"Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1- infected patients. AIDS. 2001;15(1):71\u20135.","journal-title":"AIDS."},{"key":"5802_CR11","doi-asserted-by":"publisher","unstructured":"Guo F, Cheng X, Hsieh E, Du X, Fu Q, Peng W, et al. Prospective plasma efavirenz concentration assessment in Chinese HIV-infected adults enrolled in a large multicentre study. HIV Med. 2018. https:\/\/doi.org\/10.1111\/hiv.12607.","DOI":"10.1111\/hiv.12607"},{"issue":"2","key":"5802_CR12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/QAI.0b013e3181b061e6","volume":"52","author":"M van Luin","year":"2009","unstructured":"van Luin M, Gras L, Richter C, van der Ende ME, Prins JM, de Wolf F, et al. Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations. J Acquir Immune Defic Syndr. 2009;52(2):240\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9927","key":"5802_CR13","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/S0140-6736(13)62187-X","volume":"383","author":"ENCORE1 Study Group","year":"2014","unstructured":"ENCORE1 Study Group. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet. 2014;383(9927):1474\u201382.","journal-title":"Lancet."},{"issue":"4","key":"5802_CR14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/jac\/dkn029","volume":"61","author":"C Wyen","year":"2008","unstructured":"Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008;61(4):914\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"9787","key":"5802_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","volume":"378","author":"CJ Cohen","year":"2011","unstructured":"Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378(9787):229\u201337.","journal-title":"Lancet."},{"issue":"4","key":"5802_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00228-007-0412-3","volume":"64","author":"C Nyakutira","year":"2008","unstructured":"Nyakutira C, R\u00f6shammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, et al. High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV\/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2008;64(4):357\u201365.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"5802_CR17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/FTD.0b013e3181ad74a4","volume":"31","author":"ST Liu","year":"2009","unstructured":"To KW, Liu ST, Cheung SW, Chan DP, Chan RC, Lee SS. Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese. Ther Drug Monit. 2009;31(4):527\u201330.","journal-title":"Ther Drug Monit"},{"issue":"7","key":"5802_CR18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s40262-015-0360-5","volume":"55","author":"L Dickinson","year":"2016","unstructured":"Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, et al. Comprehensive pharmacokinetic, Pharmacodynamic and Pharmacogenetic evaluation of once-daily Efavirenz 400 and 600 mg in treatment-Na \u0308\u0131ve HIV-infected patients at 96 weeks: results of the ENCORE1 study. Clin Pharmacokinet. 2016;55(7):861\u201373.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"5802_CR19","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/cid\/cit246","volume":"57","author":"AF Luetkemeyer","year":"2013","unstructured":"Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E. Relationship between weight, Efavirenz exposure, and Virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE study. Clin Infect Dis. 2013;57(4):586\u201393.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"5802_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/QAD.0000000000002067","volume":"33","author":"R Bellagamba","year":"2019","unstructured":"Bellagamba R, Giancola ML, Tommasi C, Piselli P, Tempestilli M, Angeletti C, et al. Randomized clinical trial on efficacy of fixed-dose efavirenz\/tenofovir\/emtricitabine on alternate days versus continuous treatment. AIDS. 2019;33(3):493\u2013502.","journal-title":"AIDS."},{"issue":"3","key":"5802_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1086\/510746","volume":"44","author":"RD Moore","year":"2007","unstructured":"Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44(3):441\u20136.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"5802_CR22","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/cid\/ciy176","volume":"67","author":"Y Mutoh","year":"2018","unstructured":"Mutoh Y, Nishijima T, Inaba Y, Tanaka N, Kikuchi Y, Gatanaga H, et al. Incomplete recovery of CD4 cell count, CD4 percentage, and CD4\/CD8 ratio in patients with human immunodeficiency virus infection and suppressed Viremia during long-term antiretroviral therapy. Clin Infect Dis. 2018;67(6):927\u201333.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"5802_CR23","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s10461-011-9939-5","volume":"15","author":"CA Kenedi","year":"2011","unstructured":"Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. 2011;15(8):1803\u201318.","journal-title":"AIDS Behav"},{"issue":"4","key":"5802_CR24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/QAI.0000000000000606","volume":"69","author":"N Ford","year":"2015","unstructured":"Ford N, Shubber Z, Pozniak A, Vitoria M, Doherty M, Kirby C, et al. Comparative safety and neuropsychiatric adverse events associated with Efavirenz use in first-line antiretroviral therapy: a systematic review and meta-analysis of randomized trials. J Acquir Immune Defic Syndr. 2015;69(4):422\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"5802_CR25","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1258\/ijsa.2010.010114","volume":"21","author":"J Sun","year":"2010","unstructured":"Sun J, Chen J, Yao Y, Zhang R, Zheng Y, Liu L, et al. Minimum effective plasma. Concentration of efavirenz in treatment-naive Chinese HIV-infected patients. Int J STD AIDS. 2010;21(12):810\u20133.","journal-title":"Int J STD AIDS"},{"issue":"5","key":"5802_CR26","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/01.qai.0000147523.41993.47","volume":"38","author":"CR Fumaz","year":"2005","unstructured":"Fumaz CR, Mu\u00f1oz-Moreno JA, Molt\u00f3 J, Negredo E, Ferrer MJ, Sirera G, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr. 2005;38(5):560\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"5802_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh. Sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193\u2013213.","journal-title":"Psychiatry Res"},{"issue":"7","key":"5802_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s40261-016-0399-6","volume":"36","author":"A Mowla","year":"2016","unstructured":"Mowla A, Dastgheib SA, Razeghian JL. Comparing the effects of. Sertraline with duloxetine for depression severity and symptoms: a double-blind, randomized controlled trial. Clin Drug Investig. 2016;36(7):539\u201343.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"5802_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1017\/neu.2016.33","volume":"29","author":"S Hidese","year":"2017","unstructured":"Hidese S, Ota M, Wakabayashi C, Noda T, Ozawa H, Okubo T, et al. Effects of. Chronic l-theanine administration in patients with major depressive disorder: an open-label study. Acta Neuropsychiatr. 2017;29(2):72\u20139.","journal-title":"Acta Neuropsychiatr"},{"key":"5802_CR30","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fpsyt.2018.00384","volume":"9","author":"X Huang","year":"2018","unstructured":"Huang X, Meyers K, Liu X, Li X, Zhang T, Xia W, et al. The double burdens of. Mental Health Among AIDS Patients With Fully Successful Immune Restoration: A Cross-Sectional Study of Anxiety and Depression in China. Front Psychiatry. 2018;9:384.","journal-title":"Front Psychiatry"},{"issue":"3","key":"5802_CR31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.fpc.0000189797.03845.90","volume":"16","author":"J Wang","year":"2006","unstructured":"Wang J, S\u00f6nnerborg A, Rane A, Josephson F, Lundgren S, St\u00e5hle L, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics. 2006;16(3):191\u20138.","journal-title":"Pharmacogenet Genomics"},{"issue":"12","key":"5802_CR32","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1093\/jac\/dkq369","volume":"65","author":"Y Jamshidi","year":"2010","unstructured":"Jamshidi Y, Moreton M, McKeown DA, Andrews S, Nithiyananthan T, Tinworth L, et al. Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection. J Antimicrob Chemother. 2010;65(12):2614\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"5802_CR33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1086\/655470","volume":"202","author":"HJ Ribaudo","year":"2011","unstructured":"Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis. 2011;202(5):717\u201322.","journal-title":"J Infect Dis"},{"issue":"2","key":"5802_CR34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/jac\/dkt372","volume":"69","author":"FS Sarfo","year":"2014","unstructured":"Sarfo FS, Zhang Y, Egan D, Tetteh LA, Phillips R, Bedu-Addo G, et al. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J Antimicrob Chemother. 2014;69(2):491\u20139.","journal-title":"J Antimicrob Chemother"}],"updated-by":[{"DOI":"10.1186\/s12879-021-05880-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000}}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05802-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-021-05802-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05802-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T11:02:05Z","timestamp":1617274925000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-05802-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,23]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5802"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-05802-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-100711\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,23]]},"assertion":[{"value":"7 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12879-021-05880-8","URL":"https:\/\/doi.org\/10.1186\/s12879-021-05880-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethic Committee of Peking Union Medical College Hospital approved this study and all the participant provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}